Loading patent…
AssigneeaTyr Pharma, Inc.
InventorsChi-Fang WU, Darin LEE, Jeffry D. WATKINS, Kristi PIEHL, Kyle CHIANG, Marc THOMAS, Minh-Ha DO, Ying BUECHLER, John D. MENDLEIN
Estimating the term…
The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
A histidyl-tRNA synthetase (HRS) fusion polypeptide, comprising (a) an HRS polypeptide that comprises amino acid sequence at least 80% identical to any of SEQ ID NOS:1-106, 170-181, or 185-191 or a sequence of any of Tables D1, D3-D6, or D8, and (b) at least one Fc region fused to the C-terminus, the N-terminus, or both of the HRS polypeptide.
2-33. (canceled)
41-64. (canceled)
66-75. (canceled)
78-84. (canceled)
Dependencies are inferred from the claim text.